Adhering to the core purpose of "China Innovation Global Cooperation Shanghai Trading" at the China National New Drug Conference (CPIC 2026), this conference has set up a 1V1 precision docking and communication platform. At present, we have collected over 100 buyer demands, including over 30 docking demands from overseas institutions.

To efficiently match conference resources, we are currently recruiting seller organizations for free within a limited time. The quota is limited and available on a first come, first served basis!

Limited time free period, starting from today until 50 seller institutions are recruited.

【 1V1 Limited Time Free 】 Collect up to 50 seller institutions
Registration needs to be reviewed

Target Audience
 

📍 Biomedical companies that have clear project license out requirements and meet any of the following conditions: 

✔ Listed companies, or quasi listed companies that have entered the counseling period and later stages; 

✔ Having self-developed small molecules, antibodies ADC、 Biotech companies with innovative pipelines such as gene/cell therapy and drug delivery; 

✔ Enterprises with domestic and international license out authorization experience;
✔ Enterprises with a cumulative financing amount exceeding 500 million RMB;
✔ Enterprises with FIC/BIC potential projects.

Key population types
1. Actual controller/founder of biopharmaceutical enterprises
Transfer: New drug pipeline, candidate drug projects, medical device products, partial/full equity of the company

2. CRO/CDMO/third-party laboratory holder
Seeking capacity transfer, equity mergers and acquisitions, and cooperative sales

3. PI、 Research team, patent holder
Technology authorization, project transfer, seeking acquirer

4. Asset holders of biopharmaceutical GMP factories and industrial parks
Asset transfer, overall packaging cooperation
Suitable appeals: M&A exit, external project authorization, equity transfer, technology licensing, asset sale

Nearly 200+biopharmaceutical investment institutions are in place!

📌 Global MNC representatives (partial):
Bayer China | Merck China | Johnson&Johnson Innovation | Novartis China | Eli Lilly China

📌 Top Chinese/Listed Pharmaceutical Companies (Part):
China Biopharmaceutical | Xinlitai Pharmaceutical | Shanghai Pharmaceutical Group | Kangzhe Pharmaceutical | Aosaikang Pharmaceutical | Haizheng Pharmaceutical | Jinsai Pharmaceutical

📌 Investment institutions (partially):
Hillhouse Venture Capital | Rehabilitation Capital | Pivot BioVenture Partners | Huagai Capital | CICC Capital | Yuexiu Industrial Fund | Lenovo Venture Capital | Volcanic Stone Capital | E Fund | Fengrui Venture Capital

🔔 CPIC 2026 [1v1 Appointment System] has been registered:

C-Level President/Founder accounts for 35%, and Director and above account for a total of 76%. You walk into the 1v1 appointment area, and the person sitting across from you is most likely the one who can make a decision.

68% of people come with a need for BD collaboration. Every business card and pipeline introduction you prepare may be obtained by the person who is looking for assets like you.

Pharmaceutical companies account for 42%, investment institutions account for 22%, and CXOs and suppliers account for 18% - the core roles of the entire industry chain have been registered in this system. You're not here, your competitor is most likely already here.

Supplier 15.6%, investor 12.5%, purchaser 10.2%, financing party 5.5%

The core value of the 1v1 appointment system is that all four parties are present at the same time - not randomly selected, but accurately matched based on your needs.

In response to the strong voice of the attendees
CPIC 2026 Organizing Committee officially announces
75% off ticket purchase discount originally scheduled to expire on June 30th
The time limit has been extended to 24:00 on July 10th!
This is the last return after the 618 promotion

25% off for the last 8 days! Register quickly